| Name | Keller Landing |
|---|---|
| Location | 813 Keller Lane, Tuscumbia, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 109 |
| Occupancy Rate | 53.12% |
| Medicare ID (CCN) | 015028 |
| Legal Business Name | Sunbridge Healthcare Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1699143297 |
| Organization Name | GENESIS ELDER CARE REHABILITATION SERVICES, INC |
| Doing Business As | GENESIS REHABILITATION SERVICES |
| Address | 813 Keller Ln, Tuscumbia, AL 35674 |
| Phone Number | 256-383-1535 |
News Archive
An in-depth proteomic analysis of the sera of 50 participants from the Women's Health Initiative (WHI) hormone replacement therapy trial provides some explanations for the trial's clinical results.
Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).
In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection.
"BMA Scotland supports the Scottish Government's aim to encourage a stronger sense of public ownership of the NHS and the renewed commitment to provide a service which is publicly funded and owned, free at the point of delivery. As such, we welcome the commitment to articulate the rights and responsibilities of all those using and providing NHS services.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.
› Verified 7 days ago
| NPI Number | 1750331906 |
| Organization Name | SUNBRIDGE HEALTHCARE LLC |
| Doing Business As | KELLER LANDING |
| Address | 813 Keller Ln, Tuscumbia, AL 35674 |
| Phone Number | 256-383-1535 |
News Archive
An in-depth proteomic analysis of the sera of 50 participants from the Women's Health Initiative (WHI) hormone replacement therapy trial provides some explanations for the trial's clinical results.
Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).
In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection.
"BMA Scotland supports the Scottish Government's aim to encourage a stronger sense of public ownership of the NHS and the renewed commitment to provide a service which is publicly funded and owned, free at the point of delivery. As such, we welcome the commitment to articulate the rights and responsibilities of all those using and providing NHS services.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
An in-depth proteomic analysis of the sera of 50 participants from the Women's Health Initiative (WHI) hormone replacement therapy trial provides some explanations for the trial's clinical results.
Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).
In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection.
"BMA Scotland supports the Scottish Government's aim to encourage a stronger sense of public ownership of the NHS and the renewed commitment to provide a service which is publicly funded and owned, free at the point of delivery. As such, we welcome the commitment to articulate the rights and responsibilities of all those using and providing NHS services.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $6500 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.56 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.61 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 8.93 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.46 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.33 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 84.5 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 32.52 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 21.33 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.76 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.43 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.38 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.61 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.21 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 0 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 21.28 | 82.93 |
News Archive
An in-depth proteomic analysis of the sera of 50 participants from the Women's Health Initiative (WHI) hormone replacement therapy trial provides some explanations for the trial's clinical results.
Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).
In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection.
"BMA Scotland supports the Scottish Government's aim to encourage a stronger sense of public ownership of the NHS and the renewed commitment to provide a service which is publicly funded and owned, free at the point of delivery. As such, we welcome the commitment to articulate the rights and responsibilities of all those using and providing NHS services.
Micromet, Inc. today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.
› Verified 7 days ago
Cottage Of The Shoals Location: 500 John Aldridge Drive, Tuscumbia, Alabama 35674 Phone: (256) 383-4541 |